Incannex Healthcare Inc. (IXHL): Operating Income

Annual figures by period end, from SEC filings.

-$23.03M
Year ended 2026-06-30
2023-06-30: -$49.67M2024-06-30: -$30.04M2025-06-30: -$23.79M2026-06-30: -$23.03M-$23.03M
2023-06-30 Operating Income (USD) 2026-06-30
Period endedOperating IncomeChange YoYSource filing
2026-06-30-$23.03Mn/m2026-09-25, From 2025-07-01
2025-06-30-$23.79Mn/m2026-09-25, From 2024-07-01
2024-06-30-$30.04Mn/m2025-09-29, From 2023-07-01
2023-06-30-$49.67Mn/a2024-09-30, From 2022-07-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Incannex Healthcare Inc. (IXHL)2026-06-30-$23.03Mn/m
Abbott Laboratories (ABT)2025-12-31$8.05B+18.0%
TherapeuticsMD, Inc. (TXMD)2025-12-31-$4.39Mn/m
Nature's Sunshine Products Inc (NATR)2025-12-31$24.74M+23.1%
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31-$5.29Mn/m
Lisata Therapeutics, Inc. (LSTA)2025-12-31-$18.21Mn/m
Heron Therapeutics, Inc. (HRTX)2025-12-31-$2.54Mn/m
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$2.16Bn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$231.0Kn/m

Compare IXHL, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗